Hck-IN-3

Hck-IN-3 is an orally effective inhibitor targeting HCK (KD = 3.92 μM) . Hck-IN-3 can inhibit the release of NO. Hck-IN-3 has an IC50 of 6.52 μM in RAW264.7 cells. Hck-IN-3 can inhibit the release of TNF-α, IL-6, and IL-1β in a concentration dependent manner. Hck-IN-3 downregulates the protein expression of NLRP3, ASC, pro-caspase-1, and pro-IL-1β in a concentration dependent manner. Hck-IN-3 can be used for research on acute non traumatic inflammatory conditions[1].

Product Specifications

UNSPSC

12352005

Target

Caspase; Interleukin Related; NOD-like Receptor (NLR) ; Src; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Field of Research

Inflammation/Immunology

Smiles

COC1=C(OC)C=C(C2=CC(C=CC(OC)=C3OCC4=CC=C(NC(OC(C)(C)C)=O)C=C4)=C3C=[N+]2CC5)C5=C1.[Br-]

Molecular Formula

C32H35BrN2O6

Molecular Weight

623.53

References & Citations

[1]Fan T, et al. Design and synthesis of protoberberine analogues to alleviate LPS-induced acute lung injury by targeting HCK and blocking the HCK-NLRP3 axis. Eur J Med Chem. 2025 Oct 8;302 (Pt 1) :118252.